Table 3 Incidence rates of T2DM by statin exposure status and crude and adjusted hazard ratios

All sample

2,016,094

24.24 (24.04-24.44)

11.95 (11.86-12.04)

1.99 (1.97-2.01)

1.57 (1.54-1.59)

1.57 (1.55-1.60)

PS [5-95%]

1,448,993

23.90 (23.69-24.11)

12.2 (12.01-12.31)

1.91 (1.89-1.94)

1.56 (1.54-1.59)

1.57 (1.54-1.59)

Stop

2,016,094

25.32 (25.71-26.14)

11.95 (11.86-12.04)

2.13 (2.11-2.16)

1.70 (1.67-1.72)

1.71 (1.68-1.73)

1,448,993

25.54 (25.32-25.77)

12.20 (12.10-12.31)

2.05 (2.02-2.07)

1.69 (1.66-1.71)

1.70 (1.67-1.72)

Change

2,016,094

29.38 (29.14-29.63)

12.13 (12.04-12.21)

2.42 (2.40-2.45)

1.90 (1.87-1.93)

1.91 (1.88-1.93)

1,448,993

28.98 (28.73-29.24)

12.39 (12.28-12.50)

2.33 (2.31-2.36)

1.90 (1.87-1.93)

1.91 (1.88-1.94)

First

2,016,094

23.80 (23.15-24.47)

9.69 (9.48-9.91)

2.45 (2.37-2.54)

2.15 (2.05-2.25)

2.14 (2.05-2.25)

6 months

1,448,993

23.92 (23.23-24.62)

9.86 (9.59-10.13)

2.43 (2.33-2.52)

2.18 (2.08-2.29)

2.18 (2.07-2.29)

After

2,003,499

24.28 (24.07-24.89)

12.28 (12.37-24.49)

1.95 (1.92-1.97)

1.51 (1.49-1.54)

1.52 (1.49-1.54)

6 month

1,436,377

23.89 (23.68-24.11)

12.54 (12.43-12.66)

1.86 (1.84-1.89)

1.50 (1.47-1.53)

1.51 (1.48-1.53)